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Soluble immune complexes in sera ofpateints with nephritis. Bind-
ing of radioactively labeled Clq was used to detect soluble antigen-
antibody complexes in sera collected at the time of renal biopsy
from 104 patients with immunofluorescentfindingsconsistent with
immune-complex disease. In comparison with data obtained with
sera from 85 healthy donors, significantly elevated Clq binding
activity was demonstrated in sera from 22 patients. Clq binding
was elevated in all four patients whose dominant histologic finding
on bright field microscopy was an intense interstitial mononuclear
cell infiltrate. High Clq binding activity was found preferentially in
sera from patients who had diffuse rather than focal histologic
abnormalities by light microscopy, heavy glomerular deposits of
C4 and C3 by immunofluorescence and elevated serum creatinine
concentrations, However, there were many patients with similar
immunofluorescent and bright field microscopic changes in whom
circulating complexes were not detected and there was no correla-
tion between the pattern of glomerular localization of immune
complexes and the Clq binding activity of the sera. Serial measure-
ments of Clq binding activity in the sera from three patients over a
90-day interval emphasized that immune complexes may be dem-
onstrated by this technique only intermittently in the sera of some
patients with renal biopsy evidence of immune-complex disease.
Nevertheless, these observations suggest that the Clq binding test
may be a useful tool to monitor disease activity in patients with
immunologically mediated renal disease.
Immuns complexes solubles dans le serum de malades atteints de
néphrite. La liaison du Clq marqué radioactif a été utilisée pour
déceler les complexes solubles antigène anticorps dans le serum
obtenu au moment de Ia biopsie rénale chez 104 malades pour
lesquels les constations en immuno-fluorescence Ctaient compat-
ibles avec une maladie a immuns complexes. La comparaison des
résultats avec ceux de 85 donneurs en bonne sante a montré une
augmentation significative de l'activité de liaison de Clq dans le
serum de 22 malades. La liaison de Clq était élevée chez les quatre
malades pour lesquels Ia constatation histologique principale était
one infiltration interstitielle intense faite de cellules mononuclées.
Une activité de liaison élevée de CIq a été constatée surtout dans le
serum de malades atteints d'anomalies histologiques diffuses plutôt
que focales, avec des dCpôts glomérulaires importants de C4 et de
C3 en immuno-fluorescence et dont les créatinines sériques étaient
élevées. Cependant, chez beaucoup de malades ayant les mêmes
modifications histologiques et d'immuno-fluorescence les com-
plexes circulants n'ont pas été décelables et il n'a pas été observe de
correlation entre les modalités de localisation glomérulaire des
immuns complexes et l'activité de liaison du C1q. Des mesures
repetees de l'activité de liaison de Clq dans le serum de trois
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malades sur une période de 90 jours mettent en evidence le fait que
les immuns complexes ne sont mis en evidence par cette technique
que de facon intermittente dan le serum de malades dont la biopsie
rénale montre des signes de maladie des immuns complexes. Ces
observations suggèrent, cependant, que l'épreuve de Ia liaison de
Clq peut être un instrument utile pour surveiller l'activité de
l'aIfection chez des malades atteints de néphropathies a détermi-
nisme immunologique.
Considerable clinical and experimental evidence
suggests that glomerular deposition of antigen-an-
tibody complexes is a major cause of glomerulone-
phritis [1,21. Moreover, studies in experimental
serum sickness have demonstrated that the degree
and extent of glomerular injury are closely related
to the quantity of antigen and antibody which
deposits in the glomeruli [3,4]. Nevertheless, in man
the relationship between circulating immune com-
plexes and the histologic and functional status of
the kidney has not been determined primarily due
to difficulties associated with the measurement of
soluble immune complexes in sera.
Recently, new methods to detect antigen-antibody
complexes [5—10] in sera have become available. We
have used one of these, the Clq binding method of
Nydegger et al [10], to test sera obtained at the time
of renal biopsy under the hypothesis that the magni-
tude of the Clq binding activity in sera may be related
to the extent of severity of renal disease.
Methods
Patient and control populations: Collection and
storage of sera. Among the renal biopsies submitted
for diagnostic evaluation over a period of 27 months,
immunofluorescent studies revealed that Ill patients
had glomerular deposits of immunoglobulin or com-
plement in a granular pattern consistent with im-
mune-complex disease. Sera were not available from
three patients and the clinical records were in-
complete in four cases. The remaining 104 patients
were included in this study. Clinical records were
reviewed to determine the serum creatinine concen-
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tration at the time of the biopsy, the endogenous
creatinine clearance (ECC), corrected to a body sur-
face area of 1.73 m2, the quantity of proteinuria and
the serum albumin concentration. Sera collected
from 85 healthy blood bank donors and stored under
the same conditions (—70° C) served as controls. Sera
were also collected at frequent intervals from three
patients with severe chronic glomerulonephritis hos-
pitalized for treatment with immunosuppressive
drugs. None of the patients had clinically apparent
infections at the time of the study.
Renal histology. Tissue sections cut at 4 jm from
paraffin-blocked renal biopsy specimens were stained
with hematoxylin-eosin and periodic acid-Schiff rea-
gents. Initial histologic classification was done imme-
diately after the biopsy specimen was processed. All
tissue sections were reviewed independently by one of
the authors without knowledge of the previous read-
ing. Based on the pathologists' review of the light
microscopic findings, a numerical score from 1 to 3
was assigned to the biopsy: I) within normal limits by
bright field microscopy (by immunofluorescence, as
noted previously, the glomeruli of these patients also
contained granular deposits of immunoglobulin or
complement or both); II) focal and/or segmental
glomerular abnormalities (some glomeruli were nor-
mal by bright field microscopy); and III) all glome-
ruli abnormal.
Direct immunofluorescence was performed using
reagents specific for human-IgG, -IgA, -1gM, -C3 and
-C4 [11—13]. Specificity of fluorescein-conjugated an-
tisera to immunoglobulins and complement com-
ponents was also verified using cryostat sections of
glutaraldehyde cross-linked, purified human IgG,
IgA, 1gM, Fc and Fab fragments of IgG as well as
kappa and lambda light chains. Fluorescein-con-
jugated antisera to C4 and C3 were purchased from
Meloy Laboratories (Springfield, Virginia). Their
specificity was confirmed by double diffusion in agar
gels, immunoelectrophoresis and by membrane im-
munofluorescence using sheep red blood cells coated
with antibody and purified components of human
complement. Sheep erythrocytes, antibody and com-
plement components were purchased from Cordis
Laboratories, Miami, Florida.
Anti-C4 and anti-C3 did not display immunofluo-
rescence when tested with purified insoluble immu-
noglobulins or immunoglobulin fragments at concen-
trations 20 to 60 times those used on renal tissues.
Tissue sections were examined by means of a Leitz
Orthoplan microscope fitted with Ploem optics.
All sections were evaluated for immunofluores-
cence by the same observer. Intensity of fluorescence
was recorded on a scale of I + to 3+. The location of
the fluorescence was also recorded for each con-
jugate, as follows: focal deposits: fluorescence present
in some but not all glomeruli; segmental staining:
deposits found in some but not all capillary loops
within a glomerulus; peripheral deposits: fluorescent
staining mainly localized to capillary loops in the
periphery of the glomerulus; mesangial deposits: fluo-
rescent staining localized chiefly in the stalk areas.
Frequently, patterns of staining in the same gb-
merulus differed with different antibody conjugates.
For example, deposits observed with anti-IgG or anti-
1gM might be localized to the periphery of the gbom-
erular capillary loops but deposits delineated by
anti-IgA were mainly in the mesangium. To relate
serum Clq binding activity to the location of the
immunofluorescent material in such cases, we chose
as the dominant pattern that which was revealed by
the majority of the anti-immunoglobulin and anti-
complement reagents. Among tissue sections treated
with fluorescein-conjugated anti-IgA, sufficient mate-
rial (> 3 glomeruli per section) to evaluate local-
ization and intensity of immunofluorescent staining
was available in 96 cases. Similarly, the location and
intensity of staining with anti-IgG could be evaluated
in 95 cases, with anti-IgM in 94 cases, and with anti-
C4 and anti-C3 in 85 and 88 cases, respectively.
Estimation of soluble immune complexes in sera. Clq
isolated by the method of Yonemasu and Stroud [14]
was labeled with 1251 by the iodine monochboride
method [15]. Fifty nanograms of'251-Clq was added
to 0.2 ml of sera which had previously been heat-
inactivated (56° >< 30 mm) and centrifuged at 7000 X
G for 30 mm. The binding test was performed in
duplicate according to the method of Nydegger et al
[10]. This technique takes advanatage of the fact that
the reaction product of Clq and many soluble com-
plement-fixing antigen-antibody complexes are in-
soluble in the presence of 2.5% polyethylene glycol
(PEG) whereas unreacted Clq and unaggregated im-
munogbobulins are soluble in PEG at that concen-
tration [10].
The quantity of Clq bound was estimated by a
percentage scale which took as 100% the quantity of
Clq precipitated by 10% trichboracetic acid (TCA).
% Clq bound =
(CPM 1251-Clq, experimental) — (background)
(CPM '251-Clq in 10% TCA) — (background)
>< 100.
Data were reported as the average percent of Clq
bound by duplicate samples. Variation between ex-
periments was monitored by including aliquots of
sera from the same two normal donors as negative
controls and samples containing 100 and 200 zg of
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heat-aggregated IgG (63° >< 20 mm) as positive con-
trols in each experiment. Mean Ciq binding for the
first and second of the two normal control sera were,
respectively, 3,7 0.3 and 3.6 0.3% (mean SEM,
ten experiments); 100 and 200 g of heat-aggregated
lgG bound 37.2 1.1 and 58.5 + 1.5% of Clq,
respectively (mean SEM, ten experiments). The
lower limit of sensitivity of the method, in terms of
heat-aggregated IgG was 0.5 ig using IgG which
had been purified by DEAE cellulose chromotog-
raphy [Ii] and aggregated at 63° X 20 mm at a
concentration of 5 mg/mi. Ninety-five percent of the
normal donor sera bound less than 4.7% of the added
1251-Clq. Therefore, 4.7% Clq binding was taken as
the upper limit of normal.
Since it is reported that DNA, especially single-
stranded DNA (S-DNA), may cause increased Clq
binding [10], and since DNA may be present in both
normal [17] and patient [16,24] sera, we carried out
preliminary experiments to evaluate this potential
source of false positives. S-DNA was prepared by
heating DNA (calf-thymus, Worthington Biochemi-
cals, Freehold, NJ) to 100°C in a boiling water bath
for ten minutes followed by prompt cooling to 0°C in
an ice bath. Under the standard conditions of the
test, we were unable to show in any of four experi-
ments a significant increase in Clq binding activity in
heat-inactivated normal donor sera containing con-
centrations of added S-DNA or N-DNA ranging
from 3 to 200 tg/ml of serum. Sera were tested after
heat inactivation in order to abolish competition be-
tween '251-Clq and enodgenous Clq for binding sites
on the antigen-antibody complexes and to prevent
dissipation of the '251-Clq in the native Cl complex in
the patient's serum [19,21].
Other techniques and methods. C3 concentrations
were measured by single radial diffusion in freshly
thawed, non—heat—inactivated sera using a com-
mercially available kit (Meloy Laboratories, Spring-
field, VA). Clq concentrations were also measured
by single radial diffusion in 0.75% agarose con-
taining 0.15 M NaCl and 0.OIM EDTA buffered at pH
8 with 0.05M Tris glycine using goat anti-CIq lot
231F016 (Kallested Laboratories, Chaska, MN). Se-
rial dilutions of purified Clq [14] were used as stan-
dards. The anti-C1q was specific for Clq when tested
by immunoelectrophoresis and double diffusion in
agarose gels containing 0.OIM EDTA against fresh
unheated normal human serum with purified Clq as
a standard.
Tests for statistical significance were performed by
the n onparametric K ruskal-Wallis one-way analysis
of variance, the Spearman rank correlation test and
the Mann-Whitney U test [18].
Results
Histologic studies of the kidney biopsy specimens
demonstrated immune complex-type deposits of im-
munoglobulin or complement or both in the mesan-
gium or capillaries of some glomeruli from all
patients.
Sera from 22 (21%) bound a higher percent-
age of Clq than did 95% of the healthy controls
(Table I). The highest Clq binding levels were found
in sera from patients who had diffuse (group III) as
compared to focal (group II) or minimal (group I)
histologic evidence of disease as shown by light mi-
croscopic examination of the renal biopsy specimen
(Fig. I). The differences in the Clq binding values
obtained in these three groups of patients were exam-
ined by analysis of variance [18]. Including all obser-
vations in patients, the differences in the Clq binding
measurements shown in groups 1, 11 and III, in Fig. 1,
were marginally different statistically ([H 5.36, Df
= 2, 0.05 < P < 0.101 analysis of variance [18]).
Statistical comparison of the Clq binding activities
which exceeded the 95th percentile of the normal
range, however, suggested that it was unlikely that
the apparently higher values in group Ill as com-
pared with groups I and II could be attributed to
chance alone (U = 6, P <0.002 comparing abnormal
Clq binding values in groups I and II with those in
group III, Mann-Whitney U test [18]). Clq binding
higher than detected in sera from healthy controls
was found in 13 patients with idiopathic or post-
streptococcal nephritis, in five who had glomerulo-
nephritis associated with a systemic disease and in all
four patients in whom the predominant histologic
abnormality on bright field microscopy was a diffuse
interstitial mononuclear cell infiltrate. In three of
Clq
Patien
N
ts binding
>4.7%
Glomerulonephritis 100 8
Idiopathic 72 12
with nephrotic syndrome 2 I 4
Rapidly progressive with/without
hemorrhagic pneumonitis 7 I
Poststreptococcal 6 I
Associated with systemic diseases 22 5
Systemic lupus erythematosus 14 2
Henoch-Schöenlein purpura 2 I
Chronic aggressive hepatitis
with hepatitis B antigenemia I 1
Multiple myeloma I I
Malignant melanoma I 0
Hypertension I 0
Diabetes mellitus 2 0
Interstitital nephritis 4 4
Table 1. Patient Population
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only mesangial localization of the complexes. None
of these had elevated serum Clq binding activity.
Among the others, there was no particular immu-
nofluorescent pattern which distinguished the renal
biopsy speciments of the 22 patients whose serum Clq
binding activity exceeded normal levels. However,
patients with the highest serum Clq binding activities
determined frequently had intensely fluorescent deposits of C3
and C4 (Fig. 3). With one exception, Clq binding
activity >4,7% was always found in sera of patients
whose renal biopsy specimen contained both IgG and
1gM in the glomerular immune-complex deposits.
Only a few patients had intensely fluorescent deposits
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Fig. I. CIq binding levels in sera from (N) healthy blood donors and
(I) patients with minimal, (II) focal and (III) diffuse disease as judged
by histologic examination of renal biopsy specimens by light micros-
copy. Ninety-five percent of the healthy donors had serum Clq
binding activity <4.7%
these four patients with heavy interstitial infiltrates,
bright field microscopy also revealed thickening and
fibrosis of Bowman's capsule and synechiae between
glomerular tufts and the capsule. All four had gran-
ular deposits of C3 in the glomeruli and one had
granular deposits of 1gM as well by immunofluores-
cence (Table 1).
Patterns of immune-complex localization in the
glomeruli were assessed in relationship to the serum
Clq binding activity (Fig. 2), A few patients showed
80 -
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41
2 3
IntensIty immunotluorescence
Fig. 3. C/q binding activity of sera compared to the intensity of
immunofluorescence observed with antibody reagents specific for
IgA, igG, 1gM, C4 and C3 in the patients' renal biopsy specimens.
High Clq binding activity was associated with intense glomerular
immunofluorescence for C3 and possibly for C4 as well.
B
6
4
2
Segmental
or focal
Peripheral
Mesangial
Peripheral
and mesangial
Fig. 2. Relation of serum Clq binding activity to the dominant pattern
of immune-complex localization in the glomeruli. as determined by
immunofluorescence. In 14 cases (last column on the right), the
pattern of localization was not determined.
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Fig. 4. Cli1t binding levels compared so the creatinine concentration in
serafrom the same patients. Clq binding of 4.7% indicates the upper
limit of the normal range.
of IgA in their glomeruli and serum from only one of
these contained high levels of Clq binding activity.
There was no overall correlation between the Clq
binding activity of patient sera and their creatinine
concentration (analysis of variance comparing the
ranks of the Clq binding values for the four groups
shown in Fig. 4). However, among patients whose
serum CIq binding activity exceeded the 95th percent-
ile value for normal sera, the highest binding activity
was found in sera from those with creatinine concen-
trations greater than 1.2 mg/l00 ml (Mann-Whitney
U test comparing Ciq binding activity in nine patients
whose serum creatinine concentrations were <1.2
mg/I 00 ml with those of 13 patients whose creatinine
concentrations exceeded 1.2 mg/100 ml, U = 15, P <
0.002).
Clq binding activity did not correlate with the se-
rum albumin concentration (data not shown) or the
serum concentrations of C3 and Clq (Figs. 5 and 6)
(Spearman rank correlation test). Serum Clq concen-
trations were outside the normal range in only six
patients. In 38 patients, C3 concentrations were
above those seen in the healthy controls; of these,
four had Clq binding activity >4.7%. C3 concentra-
tions in 15 patients were below the normal range and
Clq binding activity was >4.7% in six of these.
To evaluate day-to-day fluctuation in the CIq bind-
ing activity of sera from patients with immune-com-
plex disease, we studied serial serum samples from
three patients, collected at frequent intervals over a
90-day period, In one patient, a 19-yr-old boy receiv-
ing intermittent hemodialysis as a result of rapidly
progressive glomerulonephritis, the Clq binding ac-
tivity of sera exceeded 5.0% in only four of 56 samples
8
6 .
_i_
0.05 0.10 0.15 0.20 0.25
Clq concentration, mg/mi
Fig. 5. Serum Clq concentrations varied independently of the CIq
binding activity. Ninety-five percent confidence limits for the range
4.0 of normal donor sera are shown within the shaded area.
tested during the 90-day period. In the second
patient, (Fig. 7A), a 32-yr-old woman who had sys-
temic lupus erythematosus (SLE) with involvement of
the central nervous system, kidneys, skin, pleura and
pericardium, Clq binding levels exceeded the upper
limit of normal (>4.7%) only intermittently. In the
third patient (Fig. 7B), a 44-yr-old man with rapidly
progressive glomerulonephritis, Clq binding activity
of the serum remained above the upper limits of
normal throughout the period of observation. A de-
cline in the Clq binding activity of his serum, how-
ever, paralleled a decrease in proteinuria and a slight
decline in serum creatinine concentration observed
following the addition of cyclophospharnide to his
treatment program.
Discussion
Although the greatest Clq binding activity was
found in sera of patients with diffuse cortical disease
who, in many cases, had impaired renal function,
80
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4° -
I
0 1.0 2.0
C3 concentration, mg/mi
Fig. 6. Serum C3 concentrations, measured by single radial diffusion,
did not correlate with serum Clq binding activity. Ninety-five per-
cent confidence limits for the range of normal sera are shown
within the shaded area,
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plexes in a study of 40 patients who had "glomerulo-
nephritis without fibrinoid necrosis" [8]. Theo-
filopoulos et al observed that sera from 28 (67%)
of 42 patients with immune-complex nephritis con-
tained material which reacted with the C3 receptors
of the Raji continuous 8-cell line under conditions
which can detect 200 to 300 ng of aggregated IgG [9],
a level of sensitivity not appreciably greater than that
of the CIq binding method (approximately 500 ng of
aggregated IgG [10,21]). Sera from patients with
glomerulonephritis have recently been examined for
immune complexes by a method which measures the
ability of the sera to inhibit uptake of radioiodinated
heat-aggregated IgG by guinea pig macrophages [7].
Sera from 46 of 78 patients (59%) were reactive in
that series including 13 of 18 (72%) with SLE [20].
Direct comparisons of findings of the many tests for
soluble immune complexes in the same patient popu-
lation have not yet been reported. Thus, it is not clear
whether these results reflect differences in patient
populations, differences in sensitivity of the methods
or differences related to the size, immunoglobulin or
antigen composition of the immune complexes or the
presence of interfering substances.
None of the currently available techniques for
measuring soluble immune complexes are ideally sat-
isfactory. All will react with heat-aggregated or dena-
tured IgG. Those which employ Clq as a molecular
probe generally require that the sera be heat-in-
I I J
Days activated [10,19], a treatment which can make sera
Fig. 7. A, Serial Clq binding measurements (mean SD of at least
three determinations) in sera collected at frequent intervals from a
32-yr-old woman with systemic lupus erythematosus. The serum Clq
anti-complementary and conceivably may dissociate
.
complexes which are held together by low-avidity
antibodies [8]. A recently reported modification of
binding activity is compared to the level of urinary protein loss(mean SD of each week's daily 24-hr urine for protein) and the
serum creatinine concentration, measured weekly. Times of treat-
ment with prednisone (I mg/kg) and cyclophosphamide (I to 3
the Clq binding test may eliminate the requirement
. . .for heat inactivation [21]. False positive reactions
are also possible using Clq because of the ability of
mg/kg) are shown by horizontal bars. (Upper limit of normal Clq
binding activity, 4.7%.) B, Serial Clq binding measurements in sera
from a 44-yr-old man with rapidly progressive glomerulonephritis.
Clq binding activity is compared to urinary protein loss, serum
that molecule to bind to nucleic acids, bacterial prod-
.
ucts and ,other materials [10,19,21]. However, the
modifications of technique used in the present studies
creatinine concentration and treatment with prednisone and cy-
clophosphamide as in A. appear to exclude Clq binding by DNA; conceivably,.this may have accounted for the comparatively low
incidence of positive sera.
Problems with other methods may be equally as
there were many patients with similar renal histologic great. Recently it has been observed that immune
and functional characteristics whose sera did not complexes from sera of certain patients with rheuma-
bind abnormally high levels of Clq. Indeed, the in- toid arthritis and vasculitis may potentiate rather
cidence of sera which could be considered to contain than inhibit uptake of 1251-heat-aggregated IgG by
immune complexes was lower than one would expect guinea pig macrophages [22]. Thus, in using this
based on previous experience with this test in studies method one must be prepared to discriminate be-
of sera from patients with SLE and hepatitis B anti- tween two entirely opposite effects of immune com-
genemia [10]. However, using a test which measures plexes in the test system. Similarly, quantitation of
the anti-complementary activity of sera, Johnson, the uptake of immune complexes or aggregated IgG
Mowbray and Porter have reported a similar in- in the Raji cell test may be complicated by the fact
cidence (22.5%) of positive findings for immune com- that C3 or C3b in fresh human sera may promote the
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release of cell-bound complexes into the fluid phase
[23].
Whichever method has been used to measure im-
mune complexes in sera of patients with nephritis, all
studies thus far agree that soluble complexes cannot
be found invariably in sera of all patients who have
renal histologic evidence of immune-complex disease.
The quantitation provided by the Clq binding test has
encouraged us to try to relate histologic and func-
tional indices of disease severity to the amount of Clq
binding material in the sera. We postulated that se-
verity of disease might reflect both the quantity and
the frequency with which the glomeruli are bom-
barded by soluble immune complexes. The results
suggest that, even in a survey conducted at a single
time point in the evolution of the disease, high Clq
binding activity was detected in sera mainly in
patients with the more severe manifestations of renal
cortical disease.
Thus, the inability to detect immune complexes in
sera from all patients with renal biopsy evidence of
immune-complex disease may reflect not so much a
lack of sensitivity of the methods but rather differ-
ences in the etiologic agents responsible for the gb-
merular disease, or differences in host-response char-
acteristics such as differences in reticuloendothelial
function or antibody-forming capacity which may
govern the quantity of antigen-antibody complexes
produced and the rate of frequency with which they
enter the circulation.
The three cases studied longitudinally illustrate the
wide variation to be expected among individuals. The
experience with the patient with SLE suggests that
complexes may be present only intermittently in the
sera in this disease and is reminiscent of previous
longitudinal studies which measured DNA, anti-
DNA antibody and Clq precipitins in sera of patients
with SLE [24,251. The natural history of chronic
glomerulonephritis as a disease with both remissions
and exacerbations also suggests that agents or condi-
tions responsible for the formation of immune com-
plexes may be present only intermittently in the circu-
lation [1,2]. Moreover, in experimental nephritis,
intermittent injection of antigen can cause renal gb-
merular disease so long as complexes of the appropri-
ate size are formed and circulate and the capacity of
the reticuloendothelial elements outside the kidney to
remove and detoxify the complexes is exceeded
[26,271.
The assumption that soluble complexes may be
present only intermittently in sera from patients with
nephritis may partly explain why serum Clq and C3
concentrations were not depressed in patients who
had relatively high CIq binding activity. It also pro-
vides a rational basis for analyzing separately the
data from patients whose serum CIq binding activity
was higher than 95% of healthy controls. The correla-
tion of binding activity with severity of disease in
these patients suggests that further studies of this and
other methods for measuring soluble immune com-
plexes in sera are indicated in patients with various
morphologic types of glomerular and interstitial neph-
ntis. Frequent serial measurements may permit more
accurate prognosis and serve as guide to therapy.
Similarly, examination of the size distributions as
well as immunogbobulin class and the avidity of the
antibodies and the molecular characteristics of the
antigens incorporated in the circulating immune
complexes may permit more precise correlations be-
tween the types of complexes found in the sera and
the abnormalities which they produce in renal histol-
ogy. For example, experimental studies which have
related the size of circulating immune complexes to
their site of localization in the gbomerulus suggest
that relatively large immune complexes may preferen-
tially seek a subendothelial or mesangial location
whereas smaller complexes may be driven selectively
to the periphery of the glomerular capillary loops
[27].
The present data suggest that this or other means
of detecting soluble complexes in patients with vari-
ous types of renal disease may already be useful in
directing attention to conditions which previously
were not thought to be mediated by immune com-
plexes. For example, recent observations have sug-
gested that, in some cases, what has been called
interstitial nephritis on the basis mainly of light
microscopic observations may be an immune-com-
plex disease [28,291. In this regard, four patients who
were included in this series because they had gb-
merular deposits of immunoglobulin or complement
or both by immunofluorescence were found to have
interstitial mononuclear cell infiltrates as the domi-
nant lesion by light microscopy and were therefore
classified as having interstitial nephritis. The reac-
tivity of their sera with Clq, along with the im-
munofluorescence observations in these patients,
suggests that renal cortical deposition of immune
complexes may have been etiologically important in
initiating the disease or causing it to persist. Thus,
tests for circulating immune complexes may help to
identify such patients and discriminate them from
those in whom interstitial disease predominantly re-
flects the influence of cell-mediated immune respon-
ses [30].
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U.S.A.
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